Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646784 | 0.86 | RXFP1 (0.40) | RXFP1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2646379 | 0.86 | GCK (0.44) | MEN1KMT2AKCNH2GCK | |
| SCHEMBL2646506 | 0.83 | KCNH2 (0.38) | RXFP1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2662810 | 0.83 | KCNH2 (0.38) | RXFP1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2648777 | 0.81 | RXFP1 (0.38) | RXFP1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2646230 | 0.79 | RXFP1 (0.39) | RXFP1CASR | |
| SCHEMBL2646035 | 0.78 | EPHX2 (0.45) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL2646847 | 0.78 | POLB (0.54) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1418963 | 0.77 | SLC6A3 (0.50) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2646719 | 0.77 | GCK (0.64) | KCNH2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RXFP1 4564/4885SMN1; SMN2 4775/4885ALDH1A1 3347/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RXFP1 4494/4885SMN1; SMN2 4774/4885ALDH1A1 3111/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RXFP1 4564/4885SMN1; SMN2 4775/4885ALDH1A1 3347/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RXFP1 4564/4885SMN1; SMN2 4775/4885ALDH1A1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.